Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

151 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prospective randomized multicenter adjuvant dermatologic cooperative oncology group trial of low-dose interferon alfa-2b with or without a modified high-dose interferon alfa-2b induction phase in patients with lymph node-negative melanoma.
Hauschild A, Weichenthal M, Rass K, Linse R, Ulrich J, Stadler R, Volkenandt M, Grabbe S, Proske U, Schadendorf D, Brockmeyer N, Vogt T, Rompel R, Kaufmann R, Kaatz M, Näher H, Mohr P, Eigentler T, Livingstone E, Garbe C. Hauschild A, et al. Among authors: volkenandt m. J Clin Oncol. 2009 Jul 20;27(21):3496-502. doi: 10.1200/JCO.2008.21.3892. Epub 2009 May 11. J Clin Oncol. 2009. PMID: 19433681 Clinical Trial.
Depressive mood changes and psychiatric symptoms during 12-month low-dose interferon-alpha treatment in patients with malignant melanoma: results from the multicenter DeCOG trial.
Heinze S, Egberts F, Rötzer S, Volkenandt M, Tilgen W, Linse R, Boettjer J, Vogt T, Spieth K, Eigentler T, Brockmeyer NH, Hinzpeter A, Hauschild A, Schaefer M. Heinze S, et al. Among authors: volkenandt m. J Immunother. 2010 Jan;33(1):106-14. doi: 10.1097/CJI.0b013e3181b8bdb9. J Immunother. 2010. PMID: 19952950 Clinical Trial.
[Adjuvant therapy of malignant melanoma].
Hauschild A, Volkenandt M. Hauschild A, et al. Among authors: volkenandt m. Ther Umsch. 1999 Jun;56(6):324-9. doi: 10.1024/0040-5930.56.6.324. Ther Umsch. 1999. PMID: 10420815 Review. German.
Evidence-based and interdisciplinary consensus-based German guidelines: systemic medical treatment of melanoma in the adjuvant and palliative setting.
Garbe C, Hauschild A, Volkenandt M, Schadendorf D, Stolz W, Reinhold U, Kortmann RD, Kettelhack C, Frerich B, Keilholz U, Dummer R, Sebastian G, Tilgen W, Schuler G, Mackensen A, Kaufmann R. Garbe C, et al. Among authors: volkenandt m. Melanoma Res. 2008 Apr;18(2):152-60. doi: 10.1097/CMR.0b013e3282f702bf. Melanoma Res. 2008. PMID: 18337653
Health-related quality of life before and during adjuvant interferon-α treatment for patients with malignant melanoma (DeCOG-trial).
Ziefle S, Egberts F, Heinze S, Volkenandt M, Schmid-Wendtner M, Tilgen W, Linse R, Boettjer J, Vogt T, Spieth K, Eigentler T, Brockmeyer NH, Heinz A, Hauschild A, Schaefer M. Ziefle S, et al. Among authors: volkenandt m. J Immunother. 2011 May;34(4):403-8. doi: 10.1097/CJI.0b013e31821b7a4b. J Immunother. 2011. PMID: 21499123 Clinical Trial.
Long-term survival benefit after adjuvant treatment of cutaneous melanoma with dacarbazine and low dose natural interferon alpha: A controlled, randomised multicentre trial.
Stadler R, Luger T, Bieber T, Köhler U, Linse R, Technau K, Schubert R, Schroth K, Vakilzadeh F, Volkenandt M, Gollnick H, Von Eick H, Thoren F, Strannegård O. Stadler R, et al. Among authors: volkenandt m. Acta Oncol. 2006;45(4):389-99. doi: 10.1080/02841860600630954. Acta Oncol. 2006. PMID: 16760174 Clinical Trial.
30 years German Dermatologic Cooperative Oncology Group (DeCOG).
Garbe C, Schadendorf D, Tilgen W, Gutzmer R, Berking C, Mohr P, Kaufmann R, Breitbart E, Weber C, Volkenandt M, Hauschild A. Garbe C, et al. Among authors: volkenandt m. J Dtsch Dermatol Ges. 2021 Nov;19(11):1682-1697. doi: 10.1111/ddg.14628. Epub 2021 Oct 22. J Dtsch Dermatol Ges. 2021. PMID: 34677891 No abstract available.
151 results